Cosmetic Research Analysis
May’s cosmetic research was led by rigorous clinical and mechanistic evidence with practice-facing impact. A multicenter RCT plus multi-omics identified a metabolic RARα–HIC1–PCK1/2 axis through which topical tretinoin prevents hypertrophic scars. Translational hair science converged on NRF2 as a druggable node coordinating ferroptosis and disulfidptosis, while clinical care signals included a double-blind trial in rosacea where a botanical moisturizer outperformed metronidazole and a NEJM negat
Summary
May’s cosmetic research was led by rigorous clinical and mechanistic evidence with practice-facing impact. A multicenter RCT plus multi-omics identified a metabolic RARα–HIC1–PCK1/2 axis through which topical tretinoin prevents hypertrophic scars. Translational hair science converged on NRF2 as a druggable node coordinating ferroptosis and disulfidptosis, while clinical care signals included a double-blind trial in rosacea where a botanical moisturizer outperformed metronidazole and a NEJM negative RCT supporting standard-dose ivermectin for severe scabies. Procedural predictability improved with multicenter evidence of high, stable 12‑month volume retention after device-processed autologous fat transfer, alongside growing use of ultrasound and LC‑OCT for safer mapping, monitoring, and biopsy‑sparing triage.
Selected Articles
1. From RCT to mechanistic study: ATRA reverses myofibroblast activation by reprogramming glucose metabolism via HIC1 and PCK1/2 to attenuate hypertrophic scar formation.
A multicenter, double-blind RCT showed topical tretinoin is non-inferior to silicone gel for preventing hypertrophic scars, and multi-omics/in vivo studies revealed that ATRA activates RARα to upregulate HIC1 and PCK1/2, shifting fibroblast metabolism and reducing myofibroblast activation.
Impact: Connects randomized clinical efficacy with a defined, druggable metabolic axis, elevating tretinoin from empirical use to mechanism-based scar prevention.
Clinical Implications: Consider topical tretinoin as an evidence-based option for hypertrophic-scar prevention while optimizing dosing/tolerability and exploring adjuncts along the RARα–HIC1–PCK pathway.
Key Findings
- Tretinoin was non-inferior to silicone gel in a multicenter double-blind RCT.
- ATRA activates RARα, upregulating HIC1 and PCK1/2 to reprogram fibroblast metabolism.
- Reduced myofibroblast activation and scar formation were observed mechanistically.
2. NRF2 Coordinates Ferroptosis and Disulfidptosis in Dermal Papilla Cells via Redox Metabolic Reprogramming in Androgenetic Alopecia.
Cross-model preclinical data show NRF2 downregulation links redox imbalance to ferroptosis and disulfidptosis in dermal papilla cells, while dimethyl fumarate activation of NRF2 rescues hair follicle structure and growth.
Impact: Defines a unifying, druggable redox node for AGA and demonstrates pharmacologic rescue, creating a mechanistic bridge toward targeted hair-loss therapeutics.
Clinical Implications: Supports early-phase testing of NRF2 activators or NRF2-modulating topicals for AGA with attention to long-term dermatologic safety and development of redox/cell-death biomarkers.
Key Findings
- NRF2 expression is reduced in AGA across DPCs, organoids, and DHT-mouse models.
- NRF2 loss links to ferroptosis (SLC7A11–GSH–GPX4 suppression) and disulfidptosis (PPP impairment/NADPH depletion).
- Dimethyl fumarate activation of NRF2 attenuates both death programs and restores follicle structure/function.
3. Efficacy, Tolerance, and Safety of a Novel Botanical Anti-Inflammatory Moisturizer in Rosacea: Results From a Double-Blinded, Randomized Controlled Trial.
In a 12-week double-blind RCT (n=60), a barrier-supportive botanical moisturizer achieved greater reductions in erythema and inflammatory lesions than 0.75% metronidazole, with good tolerability.
Impact: Head-to-head, double-blind evidence for a non-antibiotic topical outperforming a standard therapy points to a potential shift in first-line rosacea management and antibiotic stewardship.
Clinical Implications: Consider botanical, barrier-supportive topicals as first-line or adjunct therapy for mild-to-moderate rosacea, pending confirmation in larger multicenter trials and longer follow-up.
Key Findings
- Erythema IGA reduction at Week 12: 54% (botanical) vs 23% (metronidazole).
- Inflammatory lesion reduction at Week 12: 74% vs 17%; no tolerability issues.
- Superiority evident by Week 8 across erythema and lesion counts.
4. Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies.
A blinded randomized trial (n=132) found no advantage of higher-dose ivermectin (400 μg/kg) over standard-dose (200 μg/kg) when combined with 5% permethrin for severe scabies; no safety signal identified.
Impact: Definitive negative RCT in a high-impact journal clarifies dosing standards, discouraging unnecessary escalation and informing guidelines.
Clinical Implications: Maintain standard-dose ivermectin with permethrin for severe scabies; emphasize adherence and protocolized combination therapy while extending evidence to special populations.
Key Findings
- No superiority of 400 μg/kg vs 200 μg/kg ivermectin with 5% permethrin (cure 75% vs 82%).
- Blinded randomized design with parasitologic and dermoscopic confirmation.
- No safety concerns identified with either dosing strategy.
5. A Multicenter Prospective Study of Enhanced Viability Fat Transfer for Cosmetic Augmentation and Reconstruction of the Breast.
In a 14-center prospective cohort (N=190), standardized in-line device processing yielded high, stable volumetric retention (~84–87%) from 1 to 12 months, exceeding a 70% benchmark and improving planning predictability.
Impact: Large, multicenter prospective evidence that standardizing fat processing can reliably deliver high retention reduces procedural unpredictability across cosmetic and reconstructive indications.
Clinical Implications: Adopt validated device-processing workflows to minimize overcorrection and re-treatments, improve counseling on expected volume outcomes, and standardize perioperative planning.
Key Findings
- Twelve-month mean retention ~84.8% (95% CI 83.2–86.5), above a 70% benchmark.
- Retention stabilized early and remained consistent through 12 months.
- Determinants included transfer volume, patient weight change, and graft-to-recipient volume ratio.